Are asthmatics enrolled in randomized trials representative of real-life outpatients?

Respiration

Volumn 89, Issue 5, 2015, Pages 383-389

  Battaglia, Salvatore ^a   Basile, Marco ^a   Spatafora, Mario ^a   Scichilone, Nicola ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Asthma; Randomized controlled trials; Real life outpatients

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MONTELUKAST;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; ASTHMA; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; VERY ELDERLY; YOUNG ADULT; AGE; ARRHYTHMIAS, CARDIAC; LUNG DISEASES; PATIENT SELECTION; RESEARCH SUBJECT; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANXIETY; ARRHYTHMIAS, CARDIAC; ASTHMA; CORONARY ARTERY DISEASE; DEPRESSION; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUBJECTS; RETROSPECTIVE STUDIES; SMOKING; YOUNG ADULT;

EID: 84930272218     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000375314     Document Type: Article

References (39)

1. Scichilone N, Basile M, Battaglia S, Bellia V: What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration 2014; 87: 11-17.
2. Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P: Asthma and comorbid medical illness. Eur Respir J 2011; 38: 42-49.
3. Thomson NC, Spears M: Asthma guidelines and smokers: it?s time to be inclusive. Chest 2012; 141: 286-288.
4. Thomson NC, Chaudhuri R, Livingston E: Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-833.
5. Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. 2012. http://www.ginasthma.org/.
6. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group: Can guidelinedefined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836-844.
7. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M: Effect of ADRB2 polymorphisms on response to longacting β 2 -agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-2125.
8. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC: Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123: 1480-1487.
9. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, Szefler SJ; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute: Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594-2603.
10. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-1095.
11. O?Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekström T, Bateman ED: Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
12. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O?Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
13. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG: Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753.
14. Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, Lier PA, Jorup C: Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246-256.
15. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, Bateman ED: The salmeterol/ fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97: 234-241.
16. Vogelmeier C, D?Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, Naya I, Price D: Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-828.
17. Woolcock A, Lundback B, Ringdal N, Jacques LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
18. Herland K, Akselsen JP, Skj?nsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger ?real life? population of patients with obstructive lung disease? Respir Med 2005; 99: 11-19.
19. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, Aldington S, Beasley R: External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219-223.
20. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, McSharry CP, Thomson NC: Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174: 127-133.
21. Clatworthy J, Price D, Ryan D, Haughney J, Horne R: The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009; 18: 300-305.
22. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226-230.
23. Cazzola M, Segreti A, Calzetta L, Rogliani P: Comorbidities of asthma: current knowledge and future research needs. Curr Opin Pulm Med 2013; 19: 36-41.
24. Gershon AS, Guan J, Wang C, Victor JC, To T: Describing and quantifying asthma comorbidity [corrected]: a population study. PLoS One 2012; 7:e34967.
25. Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL: Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 2011; 34: 859-867.
26. Scichilone N, Rizzo M, Benfante A, Catania R, Giglio RV, Nikolic D, Montalto G, Bellia V: Serum low density lipoprotein subclasses in asthma. Respir Med 2013; 107: 1866-1872.
27. Lee HM, Truong ST, Wong ND: Association of adult-onset asthma with specific cardiovascular conditions. Respir Med 2012; 106: 948-953.
28. Appleton SL, Ruffin RE, Wilson DH, Taylor AW, Adams RJ; North West Adelaide Cohort Health Study Team: Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting β 2 -agonists. J Allergy Clin Immunol 2009; 123: 124-130.e1.
29. Zhang B, de Vries F, Setakis E, van Staa TP: The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database. J Hypertens 2009; 27: 1485-1492.
30. Di Marco F, Verga M, Santus P, Giovannelli F, Busatto P, Neri M, Girbino G, Bonini S, Centanni S: Close correlation between anxiety, depression, and asthma control. Respir Med 2010; 104: 22-28.
31. Smith A, Krishnan JA, Bilderback A, Riekert KA, Rand CS, Bartlett SJ: Depressive symptoms and adherence to asthma therapy after hospital discharge. Chest 2006; 130: 1034-1038.
32. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL: Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-2107.
33. Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V: Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy 2013; 6: 11-21.
34. Krauskopf KA, Sofianou A, Goel MS, Wolf MS, Wilson EA, Martynenko ME, Halm EA, Leventhal H, Feldman JM, Federman AD, Wisnivesky JP: Depressive symptoms, low adherence, and poor asthma outcomes in the elderly. J Asthma 2013; 50: 260-266.
35. Rothwell PM: External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 2005; 365: 82-93.
36. Price D, Bateman ED, Chisholm A, Papadopoulos NG, Bosnic-Anticevich S, Pizzichini E, Hillyer EV, Buist AS: Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc 2014; 11(suppl 2):S92-S98.
37. Wong GW, Miravitlles M, Chisholm A, Krishnan J: Respiratory guidelines - which real world? Ann Am Thorac Soc 2014; 11(suppl 2):S85-S91.
38. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 2009; 180:E47-E57.
39. Chetta A, Olivieri D: What we talk about when we talk about randomized controlled trials. Respiration 2014; 87: 9-10.